Drugs / STI-1492
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05007418 | Oct 2022 → Dec 2025 | plasma cell myeloma | Sorrento Therapeutics, Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STI-1492 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05007418 ↗ |
| Modality | Cell therapy | “Anti-CD38 A2 KOKI DAR T cells” NCT05007418 ↗ |
| Route | Intravenous | “STI-1492 administered by a single intravenous infusion” NCT05007418 ↗ |
| Target | CD38 | “Anti-CD38 A2 KOKI DAR T cells” NCT05007418 ↗ |